Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Mach7 Technologies is an Australian medical imaging software company providing enterprise imaging platforms and vendor-neutral archives (VNA) to healthcare systems primarily in North America. The company competes in the healthcare IT space against larger players like GE Healthcare and Philips, focusing on cloud-enabled, interoperable imaging solutions. With 96% revenue growth but negative margins, Mach7 is in a high-growth, pre-profitability phase typical of healthcare software scale-ups.
Mach7 sells perpetual and subscription-based licenses for its eUnity enterprise imaging platform and VNA solutions to hospitals and healthcare networks. Revenue is generated through initial license sales (typically $500K-$3M per hospital system), followed by recurring annual maintenance contracts. The company targets mid-to-large healthcare systems seeking to consolidate imaging data across multiple facilities and integrate with electronic health records. Competitive advantage lies in cloud-native architecture and vendor-neutral approach, allowing integration with existing PACS systems from multiple vendors. Pricing power is moderate given competition from established players, but switching costs are high once implemented.
New contract wins and total contract value (TCV) announcements - particularly multi-hospital system deals above $2M
Revenue growth acceleration or deceleration relative to 90-100% growth trajectory
Progress toward operating cash flow breakeven - currently burning cash despite revenue growth
Customer retention rates and annual recurring revenue (ARR) growth - critical for SaaS valuation multiples
Geographic expansion progress, particularly penetration into US market which represents 70%+ of addressable market
Technological disruption from cloud-native competitors (AWS HealthLake, Google Cloud Healthcare API) offering integrated imaging solutions at lower cost points
Regulatory changes to healthcare interoperability standards (FHIR mandates) requiring significant R&D investment to maintain compliance
Consolidation among healthcare IT vendors - larger players like Epic, Cerner (Oracle Health) expanding into imaging could marginalize independent VNA providers
Intense competition from well-capitalized incumbents (GE Healthcare, Philips, Fujifilm) with established hospital relationships and broader product portfolios
Pricing pressure as cloud-based solutions commoditize VNA functionality - risk of margin compression even as revenue scales
Customer concentration risk common in enterprise software - loss of 1-2 major hospital system contracts could materially impact revenue given small scale
Cash burn sustainability - with negative operating margins and minimal cash flow generation, company may require additional capital raises that dilute existing shareholders
Working capital management - 2.1x current ratio is adequate but software implementation projects can create lumpy cash collection cycles
Foreign exchange exposure - Australian-listed company with majority revenue in USD creates translation risk, though likely naturally hedged through USD-denominated costs
moderate - Healthcare IT spending is more defensive than general enterprise software, as hospitals prioritize clinical systems regardless of economic conditions. However, discretionary imaging upgrades can be delayed during budget constraints. Federal healthcare spending (Medicare/Medicaid reimbursements) and hospital operating margins drive capital budgets. Economic downturns may extend sales cycles from 9-12 months to 15-18 months but rarely eliminate demand.
High sensitivity through multiple channels: (1) Valuation multiple compression - high-growth, unprofitable software trades at premium multiples that contract sharply when risk-free rates rise; (2) Hospital capital budgets - many healthcare systems finance IT investments through municipal bonds or credit facilities, making borrowing costs relevant; (3) Competitive cost of capital - Mach7's ability to fund growth through equity or debt becomes more expensive in high-rate environments. Current 2.4x Price/Sales multiple is vulnerable to rate-driven multiple compression.
Minimal direct exposure given 0.02 debt/equity ratio and 2.1x current ratio indicating strong liquidity. However, customer credit quality matters - hospital financial distress can delay payments or cause contract cancellations. Tightening credit conditions may pressure hospital operating margins, reducing discretionary IT spending budgets.
growth - Company exhibits classic high-growth, pre-profitability profile with 96% revenue growth but negative margins. Attracts momentum investors betting on healthcare IT secular trends and potential for operating leverage inflection. Small $100M market cap limits institutional ownership but appeals to venture-style public market investors. Not suitable for value or income investors given negative earnings and no dividend. Recent -19.5% one-year return suggests growth narrative under pressure, likely from broader software multiple compression.
high - Small-cap healthcare IT stock with limited liquidity on ASX. Beta likely exceeds 1.5 given growth stock characteristics and micro-cap status. Quarterly results can drive 15-25% single-day moves given binary nature of contract wins. Currency volatility adds additional risk layer for AUD-based investors in USD-revenue business.